1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer
(
- Contribution to journal › Article
- 2022
-
Mark
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
(
- Contribution to journal › Article
- 2021
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
- 2016
-
Mark
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules
(
- Contribution to journal › Article
- 2015
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
(
- Contribution to journal › Article
-
Mark
Affibody molecules for PET imaging
2015) In Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine(
- Thesis › Doctoral thesis (compilation)
- 2014
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
(
- Contribution to journal › Article